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Abstract
Hereditary spastic paraplegias (HSPs) are a group of neurological disorders characterized clinically by spasticity of lower
limbs and pathologically by degeneration of the corticospinal tract. Troyer syndrome is an autosomal recessive HSP caused
by a frameshift mutation in the spartin (SPG20) gene. Previously, we established that this mutation results in a lack of
expression of the truncated mutant spartin protein. Spartin is involved in many cellular processes and associates with
several intracellular organelles, including mitochondria. Spartin contains a conserved plant-related senescence domain at its
C-terminus. However, neither the function of this domain nor the roles of spartin in mitochondrial physiology are currently
known. In this study, we determined that the plant-related senescence domain of spartin interacts with cardiolipin but not
with two other major mitochondrial phospholipids, phosphatidylcholine and phosphatidylethanolamine. We also found
that knockdown of spartin by small interfering RNA in a human neuroblastoma cell line resulted in depolarization of the
mitochondrial membrane. In addition, depletion of spartin resulted in a significant decrease in both mitochondrial calcium
uptake and mitochondrial membrane potential in cells treated with thapsigargin. Our results suggest that impairment of
mitochondrial calcium uptake might contribute to the neurodegeneration of long corticospinal axons and the
pathophysiology of Troyer syndrome.
Citation: Joshi DC, Bakowska JC (2011) SPG20 Protein Spartin Associates with Cardiolipin via Its Plant-Related Senescence Domain and Regulates Mitochondrial
Ca
2+ Homeostasis. PLoS ONE 6(4): e19290. doi:10.1371/journal.pone.0019290
Editor: Mark R. Cookson, National Institutes of Health, United States of America
Received November 21, 2010; Accepted April 1, 2011; Published April 29, 2011
Copyright:  2011 Joshi, Bakowska. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health (grant number K22NS050137 to J.C.B.). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jbakowska@lumc.edu
Introduction
The hereditary spastic paraplegias (HSPs) are inherited
neurological disorders characterized by a common feature of
progressive spasticity in the lower limbs with degeneration of
corticospinal projections of motor neurons [1]. Troyer syndrome
(SPG20) is an autosomal recessive HSP, in which patients show
spasticity of lower limbs as well as other symptoms, including
mental retardation, dysarthria, and short stature [2]. The disease is
caused by a frameshift mutation in the spartin gene (SPG20) [3]
resulting in a lack of expression of spartin rather than expression of
a truncated protein [4], indicating that the pathogenesis of Troyer
syndrome results from a loss-of-function mechanism.
Spartin harbors two conserved domains, an MIT (microtubule
interacting and trafficking motif) domain at the N-terminus and a
plant-related senescence domain at the C-terminus [5]. Currently,
neither the function nor the binding partners of the plant-related
senescence domain are known. The following evidence suggests
that the spartin protein plays diverse roles in the biology the cell:
the presence of different structural domains within spartin [5], its
association with several intracellular organelles [6–9] and its
interaction with many binding partners [10,11]. Thus far, spartin
is known to play a role in the trafficking of the epidermal growth
factor receptor [7,8] and in the turnover of lipid droplets [12,13].
Both overexpressed and endogenous spartin have been found to
associate with endosomes [7,8], lipid droplets [8,12], and
mitochondria [6]. However, the localization of spartin in the
mitochondria is controversial; an earlier study showed that
overexpressed spartin associates with mitochondria via its C-
terminus [6], but studies by Eastman and colleagues did not
confirm those findings [12].
Mitochondria are key organelles that are critical for generating
adenosine triphosphatase (ATP) via oxidative phosphorylation;
they are also involved in regulating intracellular Ca
2+ levels and
generating reactive oxygen species (ROS). Impaired mitochondrial
function is implicated in the pathogenesis of several neurodegen-
erative diseases, including Huntington’s disease [14], amyotrophic
lateral sclerosis [15], as well as HSP7 [16] and HSP13 [17].
HSP7 is caused by a mutation in the paraplegin gene encoding
the AAA (ATPases associated with diverse cellular activities)
protease located in the inner mitochondrial membrane [18].
Paraplegin protein participates in the degradation of misfolded
proteins in the mitochondrial intermembrane space and is
important for the assembly of respiratory complexes [19].
Fibroblasts derived from HSP7 patients are more prone to oxidative
stress and show impaired activity of mitochondrial complex I
compared with fibroblasts derived from unaffected individuals [19].
HSP13 is due to a mutation in the gene encoding heat-shock
protein 60 (Hsp60) [17], a chaperonin involved in the folding of
proteins that translocate from the cytoplasm to the mitochondrial
matrix. It has been shown that decreased levels of Hsp60 activity
result in increased cell death and sensitivity to oxidative stress [20].
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potential role in mitochondrial functions are not known. In this
study we determined that endogenous spartin is localized to
mitochondria. Furthermore, we discovered that spartin, via its
plant-related senescence domain, associates with cardiolipin, a
major mitochondrial phospholipid. We found that cells depleted of
spartin and neurons derived from Spg20 knock-out (KO) mice have
depolarized mitochondrial membrane (DYm). In addition,
treatment of spartin-depleted cells with thapsigargin, which
increases the cytosolic calcium levels, resulted in decreased
capacity of mitochondrial calcium uptake and depolarization of
the mitochondrial membrane.
Results
Endogenous spartin localizes to mitochondria
We examined the subcellular localization of endogenous spartin
in the SK-N-SH neuroblastoma cell line by immunofluorescence
using a recently developed polyclonal antibody against spartin.
First, we examined the specificity of polyclonal antibodies against
human spartin by immunoblotting using cell lysates from SK-N-
SH cells treated with control or spartin siRNA1 and siRNA2.
Endogenous spartin was detected as a doublet: immunoblotting
revealed a major, strong band at ,85 kDa and a much weaker,
slower migrating band at ,95 kDa when cells were treated with
control siRNA (Figure 1A). Both bands represent endogenous
spartin because neither of them was detected when cells were
treated with spartin siRNA1 or siRNA2 (Figure 1A). These results
are in agreement with previously published data demonstrating
that the fast migrating band corresponds to spartin protein,
whereas the slow migrating band corresponds to a mono-
ubiquitinated species of spartin [7,8].
Then, we applied these anti-spartin antibodies in an immuno-
fluorescence assay. As shown in Figure 1B, confocal microscopy
analysis of SK-N-SH cells (treated with control siRNA) revealed
the immunofluorescence staining of spartin in the mitochondria as
demonstrated by colocalization of spartin’s signal with TOM20, a
mitochondrial marker. Spartin staining was also observed within
the cytoplasm. A similar staining pattern of endogenous spartin
was observed in primary human fibroblasts, myoblasts, astrocytes,
and HeLa cells (data not shown). Importantly, when SK-N-SH
cells were treated with spartin siRNA nearly no immunofluores-
cence staining of spartin was observed, which verifies the
specificity of the antibody and spartin’s localization to the
mitochondria (Figure 1C).
To confirm the expression of spartin in the cytoplasm and
mitochondria, we examined the subcellular localization of
endogenous spartin by biochemical assays. Specifically, we used
differential centrifugation to separate cell homogenates into the
heavy-membrane (enriched in the mitochondria), light-membrane
(enriched in endosomes), and cytosolic fractions with subsequent
analysis by immunoblotting. Most endogenous spartin localized to
the cytosol, but a portion of it partitioned to the mitochondria-
enriched heavy-membrane fraction, as evidenced by the presence
of a mitochondrial marker, OPA-1 and a lack of the cytosolic
marker PLC-c, in this fraction (Figure 1C). A small fraction of
endogenous spartin also localized to light-membrane (enriched in
endosomes) as demonstrated by the presence of EEA1 marker in
this fraction (Figure 1C).
The plant-related senescence domain of spartin binds to
cardiolipin
It has been shown by immunofluorescence that the C-terminus
of spartin is responsible for its association with the mitochondria
[6]. We confirmed these results using differential fractionation of
cell homogenates transfected with HA-spartin (1–408) or HA-
spartin (409–666). Immunoblotting revealed that the entire post-
nuclear pool of HA-spartin (409–666) that encompasses the C-
terminus of spartin was detected in the heavy-membrane fraction
containing mitochondria (Figure S1). In contrast, HA-spartin (1–
408) was detected exclusively in the cytosolic fraction (Figure S1).
Spartin protein has no mitochondrial targeting sequence and
might associate with these organelles through the interaction of its
C-terminus with proteins and/or phospholipids that reside in the
mitochondria. The C-terminus of spartin encompasses the plant-
related senescence domain that is conserved in many proteins in
various species including Arabidopsis thaliana suggesting of its
important function. We reasoned that this domain might bind to
mitochondrial phospholipids. To test this hypothesis, we expressed
and purified a maltose binding protein (MBP)-spartin (421–607)
(which encompasses the entire plant-related senescence domain)
fusion protein and MBP alone (Figure 2A and B). MBP-spartin
(421–607) and MBP alone (used as a negative control) were
applied in an in vitro protein-lipid overlay assay using nitrocellulose
membranes with pre-spotted phospholipids. Using anti-MBP
antibodies, we found that MBP-spartin (421–607) interacted with
cardiolipin but not with two other major mitochondrial phospho-
lipids, namely phosphatidylethanolamine and phosphatidylcholine
(Figure 2C). The negative control (MBP alone) interacted with
neither cardiolipin nor with phosphatidylethanolamine or phos-
phatidylcholine (Figure 2C). Overall, our results indicate that
spartin interacts with mitochondria via its plant-related senescence
domain, which binds to cardiolipin, a major phospholipid of the
mitochondrial membrane.
Spartin associates with outer mitochondrial membrane
Cardiolipin is a major phospholipid in the inner mitochondria
membrane, but it has been also found in the outer mitochondrial
membrane [21]. To determine the topology of spartin in the
mitochondria, we overexpressed spartin-YFP in SK-N-SH cells
and isolated mitochondrial fractions. Those fractions were either
treated or not treated with proteinase K followed by immuno-
blotting (Fig. 3A). Overexpressed spartin-YFP, TOM20, and
OPA1 were all detected in the mitochondrial fraction not treated
with proteinase K (Figure 3A). Enzymatic treatment eliminated
detection of spartin-YFP and TOM20, which are anchored to the
outer mitochondrial membrane. In contrast, OPA1, a resident
protein of the intermembrane space, was still detected, indicating
that the inner mitochondrial membrane was intact (Figure 3A).
Overall, our results suggest that spartin is associated with the outer
mitochondrial membrane (Figure 3B). Importantly, alpha-synu-
clein has also been reported to associate with cardiolipin and to
locate to the outer mitochondria membrane [22].
Depletion of spartin results in depolarization of the
mitochondrial membrane
Our previous studies found that in fibroblasts derived from
patients with Troyer syndrome there is a lack of expression of
truncated spartin protein, implying that the pathology of this
disease occurs via a loss-of-function mechanism [4]. Our present
findings show that spartin associates with mitochondria through its
binding to cardiolipin, a major mitochondrial phospholipid. These
results prompted us to investigate mitochondrial function after
knock down of spartin’s expression. Specifically, we investigated
the DYm and ATP production in cells depleted of spartin. The
mitochondrial membrane potential was monitored in live cells
using a fluorescent probe, tetramethylrhodamine methyl ester
(TMRM), as described in Materials and Methods.
Spartin Regulates Mitochondrial Ca2
+ Homeostasis
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analyzed by an observer who was ‘blind’ to the experimental
conditions. We found that the mitochondrial membrane was
depolarized in cells treated with spartin siRNA1 compared with
control siRNA-treated cells (Figure 4A). Quantitative analysis from
three independent experiments revealed that depletion of spartin
with siRNA1 resulted in ,25% lower average pixel fluorescence
intensity of TMRM compared with cells expressing physiological
levels of spartin (15463.9 vs. 11462.9, control vs. spartin siRNA1-
treated cells, respectively, p,0.01; Figure 4B). Similar results were
found when cells were treated with spartin siRNA2 (15463.9 vs.
10863.9, control vs. spartin siRNA2-treated cells, respectively,
p,0.01; Figure 4B). Importantly, all cells treated with carbonyl
cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP), a mito-
Figure 1. Endogenous spartin associates with mitochondria. (A) Detection of endogenous spartin protein in SK-N-SH cells treated with
control siRNA, spartin siRNA1, and spartin siRNA2. Cell lysates were immunoblotted with guinea pig polyclonal anti-spartin antibodies. The arrow
identifies an ,85 kD spartin protein. Even loading was confirmed by immunoblotting with anti-tubulin antibodies. Sizes of protein standards are
indicated to the left in kDa. (B) Localization of endogenous spartin to mitochondria by immunofluorescence. SK-N-SH cells were treated with control
(upper panels) or spartin siRNA (lower panels), fixed, and immunostained with anti-spartin (red) and anti-TOM20 (green) antibodies. Merged images
are shown in the far right panels. The boxed areas are enlarged and placed below. Scale bar=10 mm. (C) Cells were fractionated using differential
centrifugation. Mitochondria-enriched heavy-membrane fraction (HM), light-membrane fraction (LM), and cytosolic fraction (Cyt) were prepared as
described in Materials and Methods. 30 mg of protein from each fraction was loaded per lane and analyzed by immunoblotting using anti-spartin,
anti-OPA1 (mitochondrial marker), anti-PLC-c (cytoplasmic marker), or anti-EEA1 (endosomal marker) antibodies.
doi:10.1371/journal.pone.0019290.g001
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TMRM, reflecting a collapsed DYm (Figure 4B). We also
examined the mitochondrial membrane potential in primary
cortical neurons isolated from the wild type (WT) and Spg20
knockout mice. The lack of spartin’s expression in these mutant
mice was confirmed by immunoblotting homogenate tissue from
the brain, heart, and liver of these mice (Figure S2; Text S1; data
not shown). We determined that the mitochondria membrane in
cortical neurons from mutant mice was depolarized compared to
WT cortical neurons. Average TMRM fluorescence intensity in
cortical neurons from Spg20 KO mice was ,24% lower than that
of neurons derived from WT mice (85.8561.82 vs. 65.7361.68,
WT vs. mutant neurons, p,0.01) (Figure S5A; Text S1).
We also examined whether spartin depletion alters the levels of
ATP production. We found that spartin siRNA-treated SK-N-SH
cells showed lower levels of ATP production compared with
control siRNA-treated cells (Figure S4). However, these changes
were not statistically significant. Overall, our results suggest that
spartin plays a role in maintaining the mitochondrial membrane
potential.
High intracellular calcium levels reduce the
mitochondrial uptake of calcium and depolarize
mitochondrial membrane in spartin-depleted cells
Mitochondria and the endoplasmic reticulum (ER) play a
critical role in intracellular Ca
2+ homeostasis (reviewed in [23]).
Evidence indicates that the loss of mitochondrial Ca
2+ buffering
Figure 2. A plant-related senescence domain of spartin binds to
cardiolipin. (A) Schematic diagrams of the full-length spartin with the
MIT and the plant-related senescence domains and the MBP-spartin
(421–607) constructencompassing theplant-relatedsenescence domain.
Numbers represent the amino acid residues, showing the boundaries of
indicated domains. (B) Coomassie blue staining of affinity-purified MBP
and MBP-spartin (421–607) separated on a polyacrylamide gel. The
asterisk (*) indicates a degradation product of MBP-spartin (421–607).
Sizes ofprotein standards areindicatedtotheleft in kDa. (C) Detectionof
MBP-spartin (421–607) binding to cardiolipin but not to phosphatidyl-
ethanolamine or phosphatidylcholine in a lipid-protein overlay assay.
MBP alone (negative control) did not associate with cardiolipin,
phosphatidylethanolamine, or phosphatidylcholine.
doi:10.1371/journal.pone.0019290.g002
Figure 3. The topology of spartin’s association with the
mitochondrial membrane. (A) SK-N-SH cells were transfected with
C-terminus tagged spartin-YFP, and spartin and mitochondrial fractions
were incubated with or without proteinase K. The total cell lysates (TCL)
were immunoblotted for YFP, and mitochondrial fractions were
immunoblotted for YFP, TOM20 (in the outer mitochondrial membrane)
and OPA-1 (in the inner mitochondrial membrane). (B) A proposed
model of spartin’s association with the outer mitochondrial membrane
via its senescence domain (SD). OMM and IMM, the outer and inner
mitochondrial membrane, respectively.
doi:10.1371/journal.pone.0019290.g003
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Huntington’s disease, a neurodegenerative disorder that affects
neurons in the striatum [14,24]. Thus, to determine whether
spartin has a role in the homeostasis of mitochondrial Ca
2+,w e
induced high intracellular Ca
2+ levels by treating cells with
thapsigargin. Thapsigargin increases intracellular Ca
2+ levels by
depleting the ER Ca
2+ stores and restraining the flux of Ca
2+ to
the ER by inhibiting sarcoplasmic/endoplasmic reticular Ca
2+
ATPase [25]. Thapsigargin treatment produces experimental
conditions by which it is possible to selectively investigate
mitochondrial Ca
2+ uptake without interference from the ER.
We measured the intracellular and mitochondrial Ca
2+ levels using
fluorescent probes, Fluo3- AM and Rhod-2-AM, respectively, in
cells treated with thapsigargin (1 mM). The experiment was
conducted for 1200 seconds, and from 600 to 1200 sec, we found
significantly higher levels of Fluo3 intensity in spartin siRNA1-
treated cells than in control siRNA-treated cells (Figure 5A). At the
600-sec time point spartin-depleted cells and control cells showed
average Fluo3 fluorescence pixel intensity of 79.965.8 and
61.264.5 (p,0.05; Figure 5B) average fluorescence pixel intensity
of Fluo3, respectively. These results indicate that spartin depletion
results in high levels of intracellular Ca
2+. In contrast, the Ca
2+
levels in mitochondria determined by using Rhod-2 were
significantly lower in spartin-depleted cells compared with control
cells after stimulation with thapsigargin (Figure 6A). At 600 sec, we
detected about 30% lower Rhod-2 intensity in spartin siRNA1-
treated cells compared with cells expressing physiological levels of
spartin (29.962.0 vs. 19.663.9 normalized Rhod-2 ratios,
p,0.001; Figure 6B). Similar results were obtained in cells treated
with spartin siRNA2 (Figure S5A and S5B). In these experiments,
we acquired images for a total duration of 600 sec because, in
preliminary studies, we observed bleaching of Rhod-2 fluorescence
intensity after 600 sec of taking images. Thus, in order not to have
confounding results, we restricted the imaging time to 600 sec.
Mitochondrial Ca
2+ uptake during thapsigargin exposure was
ensured using Ruthenium red, a specific inhibitor of mitochondrial
uniporter [26]. Cells were incubated with 10 mM of Ruthenium
red for 1 hr, and Rhod-2 fluorescence was measured before and
after thapsigargin treatment (Text S1). We observed a significant
decrease in Rhod-2 fluorescence intensity in the presence of
Ruthenium red in both control and spartin siRNA-treated cells
compared with thapsigargin alone (Figure S5A). This strongly
suggests that the Ca
2+ uptake in both treatment groups occurs via
the mitochondrial uniporter.
Because lower calcium levels in mitochondria are correlated
with depolarization of the mitochondrial membrane [27], we
measured DYm in cells depleted of spartin after thapsigargin
(1 mM) treatment by using TMRM. As shown in Fig. 6C,
thapsigargin treatment led to higher depolarization of mitochon-
drial membrane in cells depleted of spartin compared with cells
expressing endogenous spartin. Data from four independent
experiments revealed that cells with knocked-down spartin had
four-fold lower TMRM fluorescence intensity than cells expressing
physiological levels of spartin (Figure 6D). Specifically, quantitative
analysis at 600 sec showed that TMRM average fluorescence
intensity was 215.263.3 and 26062.0 (normalized TMRM
ratios, p,0.001; Figure 6D) in control siRNA and spartin
siRNA1-treated cells, respectively. The TMRM average fluores-
cence intensity was also significantly lower when cells were treated
with spartin siRNA2 compared to cells treated with control siRNA
(Figure S5C and D).
To confirm these findings in another cellular model (i.e., lack of
spartin’s expression) of Troyer syndrome, we used neurons derived
from Spg20 KO mice. Thapsigargin treatment resulted in a higher
depolarization of mitochondrial membrane in primary cortical
neurons derived from Spg20 KO mice compared to neurons
obtained from WT mice. The quantitative analysis revealed 1.8-
fold lower TMRM fluorescence intensity in mutant neurons than
in WT neurons. At 1200 sec, the average TMRM fluorescence
intensity was 230.962.6 and 256.863.5 (p,0.001; Figure S3C)
in neurons derived from the WT and Spg20 KO mice, respectively.
Together, our data indicate that spartin plays an important role in
maintaining mitochondrial Ca
2+ buffering capacity and mito-
chondrial membrane potential.
Discussion
In this study, we identified the role of the Troyer syndrome
protein spartin in mitochondrial functions. We demonstrated the
binding of the conserved plant-related senescence domain of
spartin to cardiolipin, a mitochondrial phospholipid; this might be
a major means by which spartin associates with the mitochondria.
Human neuroblastoma cells depleted of spartin and cortical
neurons obtained from Spg20 KO mice showed depolarized
mitochondrial membrane. In addition, knockdown of spartin
Figure 4. Spartin depletion causes depolarization of mitochon-
drial membrane potential. (A) Representative images showing
TMRM fluorescence in SK-N-SH cells treated with control (left panel) or
spartin siRNA (right panel). The pseudocolor bar represents an intensity
scale, with black as minimum and bright yellow as maximum intensity.
(B) The graph shows the average pixel fluorescence intensity of TMRM
in cells treated with control or spartin siRNA. Cells were either treated or
not treated with FCCP as indicated. The data represent mean 6 S.E.M in
150 cells for each condition from three independent experiments
(*p.0.01).
doi:10.1371/journal.pone.0019290.g004
Spartin Regulates Mitochondrial Ca2
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2+ influx upon thapsigargin stimulation.
Our findings suggest that spartin is an important player in the
physiological function of mitochondria and that lack of spartin’s
expression in patients with Troyer syndrome might cause impaired
mitochondrial calcium handling, which could contribute to the
pathophysiology of the disease.
The subcellular localization of spartin in mitochondria has been
controversial. Two studies by Byrne’s laboratory have shown, by
immunofluorescence and immunoblotting, that overexpressed and
endogenous spartin is present in the mitochondria [6,11].
However, a study by Eastman and colleagues did not replicate
those findings [12]. By using both immunofluorescence and
differential centrifugation of cells expressing endogenous spartin,
we found that spartin localized to cytoplasm and mitochondria.
Furthermore, using a biochemical assay we showed that the C-
terminus of spartin is responsible for its association with
mitochondria. These findings agree with an earlier immunofluo-
rescence study demonstrating that the C-terminus of overex-
pressed spartin colocalizes with mitochondria [6].
Proteins that are not permanently located in the mitochondria
due to the lack of a mitochondrial targeting signal associate with
the mitochondria by two major, non-mutually exclusive mecha-
nisms: 1) they bind to the proteins that reside in the mitochondria
[28] and/or 2) they bind to phospholipids enriched in the
mitochondrial membranes [22,29]. We found that spartin,
through its plant-related senescence domain, binds to cardiolipin,
a phospholipid that is present mostly in the inner [30], and to a
lesser degree in the outer mitochondrial membrane [21]. Our
experiments examining the topology of spartin revealed that it
associates with the outer mitochondria membrane. This finding
together with the presence of a large pool of spartin in the
cytoplasm [7,8], suggests that spartin might transiently bind to
cardiolipin and/or protein(s) located on the outer mitochondrial
membrane. This would also be in agreement with our previous
findings showing that spartin is a highly mobile protein [7].
Spartin is a multifunctional protein [11] and localizes to many
subcellular compartments [6–9]. The localization of spartin to
some specific organelles is transient and becomes evident after cells
are treated with compounds that facilitate a particular physiolog-
ical change. For example, treatment of cells with epidermal growth
factor, which induces synchronized endocytosis in serum-starved
cells, facilitates distribution of spartin to the endosomes [7,8].
When cells are treated with oleic acid, it causes the formation of
lipid droplets and causes spartin to relocate from the cytoplasm to
those lipid droplets [8,12]. In cells grown in regular medium with
serum, endogenous spartin has been reported to localize to trans-
Golgi [9], midbodies during cell division [9,31], and to
mitochondria (present studies). Recently, it was reported that
spartin affects lipid droplet turnover [12,13], and in the present
study we show that spartin also regulates calcium uptake to
mitochondria. Thus, spartin’s localization to the lipid droplets and
mitochondria has biological functions and further supports the
multifaceted role of spartin in the biology of the cell.
In addition to spartin, other proteins were originally found to be
mostly present in the cytoplasm and then were also located to lipid
droplets as well as mitochondria. For example, similar to spartin,
wild-type and mutant A53T alpha-synuclein (which causes a
dominant- negative form of Parkinson’s disease), and protein
kinase C (PKC) d re-distribute from the cytoplasm to the lipid
droplets after cells are treated with oleic acid [32,33]. Whereas
PKC d translocates from the cytoplasm to the mitochondria after
cells are treated with 12-O-tetradecanoylphorbol-13-acetate [34], a
pool of alpha-synculein associates with mitochondria at steady
state [35,36]. Similar to spartin, alpha-synuclein binds to
cardiolipin and is associated with the outer mitochondrial
membrane [22].
Figure 5. Thapsigargin treatment induced high levels of intracellular calcium measured by Fluo3-AM. (A) Fluorescence changes of
Fluo3 are shown as DF and reflect the cytosolic Ca
2+ levels. Spartin (white circles) and control (black circles) siRNA-treated cells were incubated with
Fluo3-AM and stimulated (indicated by the arrow) with 1 mM of thapsigargin. An asterisk (*) indicates a significant difference in cytosolic Ca
2+ levels
between spartin and control siRNA-treated cells at the indicated time points. (B) The graph shows quantification of relative fluorescence changes of
Fluo3 signifying cytosolic Ca
2+ levels. Analysis was performed in cells treated with control (black bars) or spartin (gray bars) siRNA at baseline (before
stimulation with thapsigargin) or at 600 sec after the collection of the first image. The data represent mean 6 S.E.M in 70 cells from two independent
experiments (*p.0.05).
doi:10.1371/journal.pone.0019290.g005
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for its association with lipid droplets in the presence of oleic acid
[12] and with the mitochondria at steady state [6]. Spartin
associates with lipid droplets via binding to the TIP-47 protein
[12], a structural protein in lipid droplets [37]. However, the
amino acid region that is responsible for spartin’s binding to the
TIP-47 protein remains to be determined. In the present study, we
determined that spartin through its plant-related senescence
domain (amino acids 423–607) binds to cardiolipin, suggesting
that this might be the means by which spartin associates with the
mitochondria.
An important finding of our study is that acute depletion of
spartin by siRNA significantly decreased mitochondrial Ca
2+
uptake capacity. It is well known that mitochondrial Ca
2+
buffering is controlled mainly by mitochondrial membrane
potential, which provides the driving force for Ca
2+ to enter the
Figure 6. Increased intracellular Ca
2+ levels result in mitochondrial dysfunction in SK-N-SH cells depleted of spartin. (A) Fluorescence
changes of Rhod-2 intensities are shown as DF and signify the mitochondrial Ca
2+ levels. Control (black circles) and spartin (white circles) siRNA-
treated cells were incubated with Rhod-2-AM and stimulated (indicated by the arrow) with 1 mM of thapsigargin. Error bars represent S.E.M.
(**p,0.001). (B) The graph shows quantification of relative fluorescence changes of Rhod-2 signifying mitochondrial Ca
2+ levels. Analysis was
performed in cells treated with control (black bars) or spartin (gray bars) siRNA at baseline (before stimulation with thapsigargin) or at 600 sec after
the start of the experiment. **p,0.001. The data represent mean6 S.E.M in 80 cells from three different experiments. (C) Fluorescence changes of
TMRM intensities are shown as DF and determine the mitochondrial membrane potential. Black and white circles as in (A). Cells were stimulated
(indicated by the arrow) with 1 mM of thapsigargin. **p,0.001. (D) The graph shows quantification of relative fluorescence changes of TMRM
signifying the levels of mitochondrial membrane potential. Analysis was done in cells treated with control (black bars) or spartin (gray bars) siRNA at
baseline (before stimulation with thapsigargin) and at 600 sec after taking the first image. The data represent mean 6 S.E.M in 100 cells from four
independent experiments (**p,0.001).
doi:10.1371/journal.pone.0019290.g006
Spartin Regulates Mitochondrial Ca2
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2+ uniporter (reviewed in [38]). In pathological
conditions, the efflux of Ca
2+ from the mitochondrion occurs via
the mitochondrial permeability transition pore (MPTP), which is
opened by several factors, including depolarized mitochondrial
membrane potential, high levels of ROS in mitochondria, and/or
high levels of Ca
2+ in the matrix [39]. Thus, two possible scenarios
could account for poor mitochondrial Ca
2+ handling in cells
depleted of spartin. First, the lack of spartin’s expression might
lead to diminished Ca
2+ uptake through the uniporter because of
the depolarized mitochondrial membrane potential. Alternatively,
a rapid influx of calcium might open the MPTP thereby
permitting the release of Ca
2+ to the cytosol. The latter mechanism
has been reported to be responsible for the low uptake of Ca
2+ by
mitochondria in striatal neurons derived from a murine model of
Huntington’s disease [40]. Treatment with MPTP inhibitors
significantly improved mitochondrial Ca
2+ uptake in mutant
huntingtin-expressing striatal neurons [40]. We are currently
investigating molecular mechanisms by which spartin might
regulate Ca
2+ uptake to the mitochondria.
In summary, we demonstrate the localization of spartin to
mitochondria and the functional role of spartin in maintaining
mitochondrial Ca
2+ buffering capacity and mitochondrial mem-
brane potential. Spartin is also involved in trafficking of cargo
receptors [7,8] and in the turnover of lipid droplets [12,13]. It is
reasonable to suggest that several cellular dysfunctions due to lack
of spartin’s expression contribute to a complex constellation of
phenotypic symptoms present in patients with Troyer syndrome.
We have just begun to determine specific functions of spartin at
the cellular level, and the future experiments will parse out the
different aspects of spartin’s biological role, including its role in
mitochondrial function, on the integrity of the corticospinal axons.
Materials and Methods
Cell Culture and Transfection
SK-N-SH cells were maintained in Minimal Essential Medium
(MEM) (Mediatech, Inc., Manassas, VA) supplemented with 10%
fetal bovine serum (Gemini BioProducts, West Sacramento, CA)
and essential amino acids (Invitrogen, Carlsbad, CA). The
transfections with DNA plasmids and siRNA were performed
using Lipofectamine and Lipofectamine RNAiMAX (Invitrogen),
respectively, according to the manufacturer’s instructions. The
hemagglutinin (HA)-tagged full-length spartin, HA-spartin 1–408,
and spartin-yellow fluorescence protein (YFP) in YFP-N1 were
described previously [7]. All functional experiments were per-
formed using control and spartin siRNA1 and siRNA2, the
sequences of which we described previously [7]. To generate the
pGW1-HA-tagged human spartin 409–666 construct, we used
PCR, and the amplified DNA was cloned in-frame to an EcoRI site
into the pGW1-HA vector.
Antibodies and Reagents
To generate polyclonal antibodies against human spartin, we
subcloned human spartin (108–367) into a pGEX-6p-1 vector and
expressed the glutathione S-transferase (GST) fusion protein in
BL21 E. coli bacteria as described previously [10]. The protein was
purified, digested with PreScission Protease (GE Healthcare,
Waukesha, WI), eluted, and injected into guinea pigs to produce
polyclonal antisera (Veritas Labs, Rockville, MD). We purified the
anti-spartin IgG fraction using protein A-Sepharose (Sigma-
Aldrich, St. Louis, MO). The following primary antibodies were
used: mouse monoclonal anti-optic atrophy 1 (OPA1; BD
Biosciences, San Jose, CA), mouse anti-early endosome antigen
1 (EEA1; BD Biosciences), anti-phospholipase C-c (PLC- c;
Upstate Biotechnology, Lake Placid, NY), rabbit polyclonal anti-
HA-epitope (Abcam, Cambridge, MA), mouse monoclonal anti-
translocase of the outer membrane 20 (TOM20; BD Biosciences),
mouse monoclonal anti-b-tubulin (clone 6G7) (Developmental
Studies Hybridoma Bank, University of Iowa, IA), mouse anti-
YFP (Covance, Princeton, NJ) and mouse anti-maltose binding
protein (MBP) (New England BioLabs, Ipswich, MA). The anti-
rabbit, anti-mouse, or anti-guinea pig antibodies conjugated to
horseradish peroxidase (HRP) were from Thermo Fischer
Scientific (Waltham, MA). The secondary antibodies used for
immunofluorescence included anti-mouse, anti-rabbit, or anti-
guinea pig conjugated to Alexa Fluor 488 or 555 (Invitrogen).
Thapsigargin was purchased from Enzo Life Sciences (Plymouth
Meeting, PA) and FCCP and proteinase K were obtained from
Sigma-Aldrich.
Subcellular Fractionation and Protease Digest
To detect endogenous spartin in different subcellular fractions,
cells were washed with ice-cold phosphate-buffered saline (PBS;
pH 7.4) containing 1 mM EDTA, harvested, and resuspended in
buffer A (210 mM mannitol, 70 mM sucrose, 1 mM EDTA,
10 mM HEPES, pH 7.5 with protease inhibitors) then disrupted
using a Dounce homogenizer (30 strokes). The homogenate was
centrifuged at 9006 g for 5 min, and the supernatant was
recentrifuged at 9006 g for 5 min to remove the unbroken cells
and nuclei. The post-nuclear fraction was centrifuged at 10,0006g
for 10 min, yielding a heavy-membrane fraction (HM) and
supernatant that was subsequently centrifuged at 100,0006 g,
generating light-membrane (LM) and cytosolic fractions. The
protein concentrations were measured by bicinchoninic acid
protein assay (Thermo Fisher Scientific), and 30 mg of total
protein from each fraction was resolved on 8% SDS-PAGE gel.
The presence of spartin, OPA1 (a mitochondrial marker), and
phospholipase C-c (a cytosolic marker) was analyzed by immuno-
blotting. To determine the localization of spartin in the
mitochondrial membranes, SK-N-SH cells were overexpressed
with spartin-YFP vector. The isolated mitochondrial fractions
were either treated or not treated with proteinase K (50 mg/ml) on
ice for 30 min, and the reaction was stopped by adding 5 mM of
phenylmethylsulfonyl fluoride (PMSF) as described previously
[41]. Equal amount of proteins (30 mg) from the mitochondrial
fraction treated with or without the enzyme were resolved on
SDS-PAGE gradient gel (Invitrogen). The presence of overex-
pressed spartin-YFP, OPA1 (localized in the mitochondrial
intermembrane space), and TOM20 (localized in the outer
mitochondrial membrane) was analyzed by immunoblotting.
Lipid-Protein Overlay Assay
Spartin construct 421–607 was cloned into a pMal-5 vector,
using BamHI and EcoRI restriction sites at the 59 and 39- ends,
respectively. The MBP–spartin 421–607 or MBP alone was
expressed in E. coli BL21 cells, incubated with amylase resin (New
England BioLabs) overnight at 4uC while rocking, and then eluted
according to the manufacturer’s instructions. The nitrocellulose
membrane with spotted lipids, including cardiolipin and a solvent
blank control, were purchased from Echelon Biosciences (Salt
Lake City, UT). The membrane was wetted in molecular biology
grade water, then equilibrated with Tris-buffered saline Tween-20
(TBST) for 5 min and subsequently incubated with blocking
solution as described previously [42]. Then the membrane was
incubated with 2 mg/ml of MBP-spartin 421–607 or MBP in
TBST overnight at 4uC. The following day the membrane was
washed in TBST, incubated with primary anti-MBP antibody for
1 hr, washed, and incubated with anti-mouse antibody conjugated
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with enhanced chemiluminescence (Thermo Fisher Scientific) and
exposed to film.
Immunofluorescence
SK-N-SH cells were grown on glass cover slips, fixed with 4%
paraformaldehyde for 25 min, and processed as described
previously [10]. Cover slips were mounted with ProLong Antifade
reagent (Invitrogen), and images were acquired using a Zeiss
LSM-510 confocal microscope with a 636 1.4 NA Plan
Apochromat oil immersion objective at 102461024 resolution.
The images were processed with Adobe Photoshop 7.0 software
(Adobe, San Jose, CA).
Measurement of Mitochondrial Membrane Potential in
Live Cells
Mitochondrial membrane potential was measured by the
potentiometric fluorescent probe, tetramethylrhodamine methyl
ester (TMRM; Invitrogen), which accumulates in the mitochon-
drial inner and outer membrane based on DYm and can be
detected using live cell imaging [43–45]. Cells treated with control
or spartin siRNA for 48 hrs were incubated with TMRM (50 nM)
in Tyrode’s buffer (TB) (145 mM NaCl, 5 mM KCl, 10 mM
glucose, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.4)
for 30 min at room temperature. The same concentration of
TMRM was present throughout the experiment. The culture
dishes with a glass bottom (MatTek Corporation, Ashland, MA)
were placed over the mounting chamber, and a field containing
15–20 cells was selected. Fluorescence imaging was performed
using confocal microscopy (LSM 510, Carl Zeiss MicroImaging
Inc, Thornwood, NY). The observer who acquired the images was
‘blind’ to the experimental conditions. Images from randomly
selected fields were collected by using a 406 water immersion
objective at 514/570 nm excitation/emission with an argon laser
at 5% transmission and 2566256 resolution. Images were
acquired with identical instrument settings across all samples to
ensure the comparability between experimental groups. The
fluorescence images were collected for 1 sec at an interval of
59 sec and axial resolution of 3.0 mm, to increase the optical
thickness, and a pixel depth of 12 bits. About 25–30 mitochondrial
structures were chosen as regions of interest (ROIs) in each cell
and pixel intensity of TMRM fluorescence in these regions was
averaged after background subtraction. The decrease in average
pixel intensity of TMRM fluorescence in mitochondrial regions of
interest (ROIs) was interpreted to signify the depolarization of the
mitochondrial membrane potential. Mitochondrial localization of
TMRM was confirmed by using a protonophore FCCP, which
eliminates the TMRM fluorescence from mitochondria by
collapsing the mitochondrial membrane potential. In our time
series experiment, after subtracting the background fluorescence,
the changes in TMRM fluorescence intensity were calculated
using the formula DF=F2F0/F06100, where F0 is the initial
fluorescence and F is the fluorescence intensity at any time point
[46,47].
Intracellular and mitochondrial Ca
2+ measurements
Intracellular and mitochondrial Ca
2+ were measured with the
Ca
2+-sensitive fluorescent probes Fluo3- acetoxymethyl (AM) ester
and Rhod-2 AM (Invitrogen) , respectively, as described previously
with minor modifications [48–50]. Briefly, SK-N-SH cells grown
in dishes with a glass bottom (MatTek Corporation) were washed 3
times with TB and incubated with Fluo-3AM (5 mM) containing
0.02% pluronic acid in TB at 37uC for 30 min [50,51]. Then cells
were washed 4 times with TB and incubated in the dark for
45 min to complete de-esterification of AM ester by intracellular
esterases to ensure the binding of the probe to free intracellular
Ca
2+ [52]. To measure the mitochondrial Ca
2+, Rhod-2 AM was
reduced to dihydrorhod-2 by adding a small amount of sodium
borohydrite (NaBH4, a stock of 1 mg/ml was prepared in
methanol) which is known to increase the mitochondrial loading
of the probe [49,53]. Cells were incubated with 5 mM of reduced
Rhod-2 AM containing 0.02% pluronic acid for 60 min in TB
then washed 4 times with TB and incubated in MEM for another
6 hrs. We determined the 6-hr incubation time for SK-N-SH cells
empirically, because during that time the Rhod-2 dye was present
predominantly in the mitochondria, as indicated by its colocaliza-
tion with MitoTracker Green FM (100 nM). A field containing a
minimum of 15–20 cells was selected for the experiments. The
images were acquired using 488/515 nm and 561/580 nm,
excitation/emission for Fluo-3 and Rhod-2, respectively, with
the laser power and resolution as described for mitochondrial
membrane potential. The fluorescence images were collected for
1 sec at an interval of 59 sec or 29 sec to measure the cytosolic
and mitochondrial Ca
2+ levels at an axial resolution of 3 mm and a
pixel depth of 12 bits. The change in fluorescence intensity (DF)
was calculated similarly to that for TMRM.
Statistical analysis
Data analysis was carried out using Sigma plot software (Systat
Software Inc, Chicago, IL). The data were represented as mean 6
SEM, calculated from 3–5 experiments. To calculate statistical
significance, we used Student’s t-test, and p#0.05 was considered
significant.
Detection of ATP
ATP levels were measured using an ATPLite kit (Perkin Elmer)
according to the manufacture’s instructions. The kit contains
luciferin and luciferase reagents to detect ATP by biolumines-
cence. Luminescence was measured in a Bio-Tek luminometer.
[54]
Supporting Information
Figure S1 The association of spartin with mitochondria
using fractionation. (A) Schematic diagrams of HA-tagged full-
length spartin and deletion constructs encompassing microtubule
interacting and trafficking (MIT) and/or plant-related senescence
domain studied in a mitochondrial fraction. Numbers represent
the amino acid residues, showing the boundaries of MIT and
plant-related senescence domain. (B) SK-N-SH cells were
transfected with indicated constructs of spartin, and the post-
nuclear total homogenates (T) were fractionated into soluble (S)
and mitochondria-enriched heavy-membrane fractions (HM) and
immunoblotted with anti-HA antibodies. Sizes of protein stan-
dards are indicated to the left in kDa.
(TIF)
Figure S2 Analysis of expression of spartin in brain
tissue from WT and Spg20 KO mice. Brain tissues from wild
type (WT) and Spg20 KO mice were homogenized and
immunoblotted with anti-spartin (upper panel) and b- tubulin
antibodies (lower panel).
(TIF)
Figure S3 Depolarization of mitochondrial membrane
potential in cultured primary cortical neurons derived
from Spg20 KO mice. (A) Average pixel fluorescence intensity
of TMRM from randomly selected mitochondrial regions in WT
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not treated with the mitochondrial uncoupler, FCCP. (B) Changes
in TMRM fluorescence intensity before and after treatment with
1 mM thapsigargin (indicated by arrow) in WT (black circle) and
Spg20 mutant (white circle) neurons. (C) Bar graphs showing the
relative fluorescence changes of TMRM representing the levels of
mitochondrial membrane potential. Analysis was carried out in
WT (black bars) or Spg20 mutant (gray bars) neurons at baseline
(before stimulation with thapsigargin) and at 1200 sec after taking
the first image. The data represent mean 6 S.E.M in 75 neurons
from three independent experiments (**p,0.001).
(TIF)
Figure S4 The levels of ATP in SK-N-SH cells treated
with control or spartin siRNA. Cells were treated with siRNA
for 48 hrs and ATP levels were measured using ATPlite
luminescence assay kit (PerkinElmer) according to the manufac-
turer’s protocol. Data represent mean 6 SEM luminescence in
triplicate treatment groups.
(TIF)
Figure S5 High intracellular Ca
2+ levels cause mito-
chondrial dysfunction in spartin depleted SK-N-SH cells.
(A) Changes in Rhod-2 fluorescence intensities (DF) upon 1 mM
thapsigargin exposure in control siRNA (black circle) and spartin
(white circle) siRNA2-treated cells. Fluorescence changes of Rhod-
2 intensities were also measured in siRNA treated cells in the
presence of mitochondrial Ca
2+ uniporter blocker, Ruthenium
red, prior to their stimulation with thapsigargin. Control siRNA
(black triangles) and spartin siRNA (white triangles) depict changes
in Rhod-2 fluorescence intensity upon thapsigargin exposure in
cells treated with Ruthenium red. (B) The bar graph shows
quantification of relative changes in Rhod-2 fluorescence intensity
indicating the mitochondrial Ca
2+ levels. Analysis was performed
at baseline (before thapsigargin treatment), at 600 sec after the
start of the experiment in control (black bars) and spartin siRNA2
(grey bars)-treated cells. Treatment groups are indicated on the
X-axis. The data represent mean6 S.E.M in 80 cells from two
different experiments (**p,0.001). (C) Changes in TMRM
fluorescence intensity (DF) upon 1 mM thapsigargin treatment
(indicated by the arrow) in control (black circles) and spartin
siRNA2 (white circles)-treated cells. (D) Bar graph representing the
quantification of relative fluorescence changes of TMRM (DF) at
baseline (before thapsigargin treatment) and at 600 sec after taking
the first image in control (black bars) and spartin siRNA2 (grey
bars) treated cells. The data represent mean 6S.E.M in 100 cells
from three independent experiments (**p,0.001).
(TIF)
Text S1
(DOC)
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